Insulin resistance in chronic kidney disease: A systematic review

American Journal of Physiology - Renal Physiology

Volumn 311, Issue 6, 2016, Pages F1087-F1108

  Spoto, Belinda ^a   Pisano, Anna ^a   Zoccali, Carmine ^a  

^a CNR   (Italy)

Author keywords

Chronic kidney disease; Insulin resistance; Insulin sensitivity

Indexed keywords

ADIPOCYTOKINE; INSULIN; VITAMIN D;

ANEMIA; BLOOD VESSEL FUNCTION; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE FLORA; KIDNEY FAILURE; METABOLIC ACIDOSIS; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PHYSICAL INACTIVITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VALIDITY; VITAMIN D DEFICIENCY; CHRONIC KIDNEY FAILURE; COMPLICATION; GLUCOSE CLAMP TECHNIQUE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

DISEASE PROGRESSION; GLUCOSE CLAMP TECHNIQUE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; OXIDATIVE STRESS; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D DEFICIENCY;

EID: 85002802495     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00340.2016     Document Type: Review

References (231)

1. Akalin N, Koroglu M, Harmankaya O, Akay H, Kumbasar B. Comparison of insulin resistance in the various stages of chronic kidney disease and inflammation. Ren Fail 37: 237–240, 2015.
2. Aksentijevic D, Bhandari S, Seymour AM. Insulin resistance and altered glucose transporter 4 expression in experimental uremia. Kidney Int 75: 711–718, 2009.
3. Alcelik A, Tosun M, Ozlu MF, Eroglu M, Aktas G, Kemahli E, Savli H, Yazici M. Serum levels of omentin in end-stage renal disease patients. Kidney Blood Press Res 35: 511–516, 2012.
4. Allegra V, Mengozzi G, Martimbianco L, Vasile A. Early and late effects of erythropoietin on glucose metabolism in maintenance hemodialysis patients. Am J Nephrol 16: 304–308, 1996.
5. Allegra V, Mengozzi G, Martimbianco L, Vasile A. Glucose-induced insulin secretion in uremia: relation with acid-base balance and effects of bicarbonate administration. Nephron 63: 43–48, 1993.
6. Anderson PW, Zhang XY, Tian J, Correale JD, Xi XP, Yang D, Graf K, Law RE, Hsueh WA. Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells. Kidney Int 50: 745–753, 1996.
7. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79–83, 1999.
8. Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, Meyer TW. Colonic contribution to uremic solutes. J Am Soc Nephrol 22: 1769–1776, 2011.
9. Atamer A, Alisir Ecder S, Akkus Z, Kocyigit Y, Atamer Y, Ilhan N, Ecder T. Relationship between leptin, insulin resistance, insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in patients with chronic kidney disease. J Int Med Res 36: 522–528, 2008.
10. Axelsson J, Bergsten A, Qureshi AR, Heimburger O, Barany P, Lonnqvist F, Lindholm B, Nordfors L, Alvestrand A, Stenvinkel P. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 69: 596–604, 2006.
11. Bailey JL, Zheng B, Hu Z, Price SR, Mitch WE. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/ phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol 17: 1388–1394, 2006.
12. Banerjee D, Recio-Mayoral A, Chitalia N, Kaski JC. Insulin resistance, inflammation, and vascular disease in nondiabetic predialysis chronic kidney disease patients. Clin Cardiol 34: 360–365, 2011.
13. Bardos JI, Ashcroft M. Negative and positive regulation of HIF-1: a complex network. Biochim Biophys Acta 1755: 107–120, 2005.
14. Baricos WH. Chronic renal disease: do metalloproteinase inhibitors have a demonstrable role in extracellular matrix accumulation? Curr Opin Nephrol Hypertens 4: 365–368, 1995.
15. Baum M. Insulin stimulates volume absorption in the rabbit proximal convoluted tubule. J Clin Invest 79: 1104–1109, 1987.
16. Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser D. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 16: 1091–1098, 2005.
17. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocytesecreted protein Acrp30 enhances hepatic insulin action. Nat Med 7: 947–953, 2001.
18. Bergman RN, Hope ID, Yang YJ, Watanabe RM, Meador MA, Youn JH, Ader M. Assessment of insulin sensitivity in vivo: a critical review. Diabetes Metab Rev 5: 411–429, 1989.
19. Bertrand L, Horman S, Beauloye C, Vanoverschelde JL. Insulin signalling in the heart. Cardiovasc Res 79: 238–248, 2008.
20. Biolo G, Guarnieri G, Barazzoni R, Panzetta G. Complete correction of anemia by erythropoiesis-stimulating agents is associated with insulin resistance in hemodialysis patients. Clin Exp Med 11: 181–187, 2011.
21. Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 63: 1852–1860, 2003.
22. Boden G, Lebed B, Schatz M, Homko C, Lemieux S. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 50: 1612–1617, 2001.
23. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 174: 5789–5795, 2005.
24. Borazan A, Binici DN. Relationship between insulin resistance and inflamation markers in hemodialysis patients. Ren Fail 32: 198–202, 2010.
25. Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 119: 84–90, 1986.
26. Cao L, Mou S, Fang W, Gu L, Huang J, Gu A, Qian J, Ni Z. Hyperleptinaemia, insulin resistance and survival in peritoneal dialysis patients. Nephrology (Carlton) 20: 617–624, 2015.
27. Caravaca F, Cerezo I, Macias R, Garcia de Vinuesa E, Martinez del Viejo C, Villa J, Martinez Gallardo R, Ferreira F, Hernandez- Gallego R. Insulin resistance in chronic kidney disease: its clinical characteristics and prognosis significance [in Spanish]. Nefrologia 30: 661–668, 2010.
28. Catalano C, Muscelli E, Quinones Galvan A, Baldi S, Masoni A, Gibb I, Torffvit O, Seghieri G, Ferrannini E. Effect of insulin on systemic and renal handling of albumin in nondiabetic and NIDDM subjects. Diabetes 46: 868–875, 1997.
29. Cecchin F, Ittoop O, Sinha MK, Caro JF. Insulin resistance in uremia: insulin receptor kinase activity in liver and muscle from chronic uremic rats. Am J Physiol Endocrinol Metab 254: E394–E401, 1988.
30. Chan DT, Watts GF, Irish AB, Ooi EM, Dogra GK. Insulin resistance and the metabolic syndrome are associated with arterial stiffness in patients with chronic kidney disease. Am J Hypertens 26: 1155–1161, 2013.
31. Chen CC, Li TC, Li CI, Liu CS, Wang HJ, Lin CC. Serum resistin level among healthy subjects: relationship to anthropometric and metabolic parameters. Metabolism 54: 471–475, 2005.
32. Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, Whelton PK, He J. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 14: 469–477, 2003.
33. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91: 295–299, 2006.
34. Chen S, Chen Y, Liu X, Li M, Wu B, Li Y, Liang Y, Shao X, Holthofer H, Zou H. Association of insulin resistance with chronic kidney disease in non-diabetic subjects with normal weight. PLoS One 8: e74058, 2013.
35. Cheng HT, Huang JW, Chiang CK, Yen CJ, Hung KY, Wu KD. Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly. J Clin Endocrinol Metab 97: 1268–1276, 2012.
36. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46: 459–469, 2003.
37. Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala MW, Parlow AF, Cheeseboro L, Ding YY, Russell RG, Lindemann D, Hartley A, Baker GR, Obici S, Deshaies Y, Ludgate M, Rossetti L, Scherer PE. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145: 367–383, 2004.
38. Conti FG, Striker LJ, Lesniak MA, MacKay K, Roth J, Striker GE. Studies on binding and mitogenic effect of insulin and insulin-like growth factor I in glomerular mesangial cells. Endocrinology 122: 2788–2795, 1988.
39. Corcoran A, Cotter TG. Redox regulation of protein kinases. FEBS J 280: 1944–1965, 2013.
40. Cusumano AM, Bodkin NL, Hansen BC, Iotti R, Owens J, Klotman PE, Kopp JB. Glomerular hypertrophy is associated with hyperinsulinemia and precedes overt diabetes in aging rhesus monkeys. Am J Kidney Dis 40: 1075–1085, 2002.
41. Davis TA, Klahr S, Karl IE. Glucose metabolism in muscle of sedentary and exercised rats with azotemia. Am J Physiol Renal Fluid Electrolyte Physiol 252: F138–F145, 1987.
42. de Boer IH, Katz R, Chonchol MB, Fried LF, Ix JH, Kestenbaum B, Mukamal KJ, Peralta CA, Siscovick DS. Insulin resistance, cystatin C, and mortality among older adults. Diabetes Care 35: 1355–1360, 2012.
43. de Boer IH, Mehrotra R. Insulin resistance in chronic kidney disease: a step closer to effective evaluation and treatment. Kidney Int 86: 243–245, 2014.
44. de Boer IH, Sachs M, Hoofnagle AN, Utzschneider KM, Kahn SE, Kestenbaum B, Himmelfarb J. Paricalcitol does not improve glucose metabolism in patients with stage 3–4 chronic kidney disease. Kidney Int 83: 323–330, 2013.
45. de Boer IH, Zelnick L, Afkarian M, Ayers E, Curtin L, Himmelfarb J, Ikizler TA, Kahn SE, Kestenbaum B, Utzschneider K. Impaired glucose and insulin homeostasis in moderate-severe CKD. J Am Soc Nephrol 27: 2861–2871, 2016.
46. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56: 1655–1661, 2007.
47. de Vinuesa SG, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, Lahera V, Gomez-Campdera F, Luno J. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol 17, Suppl 3: S206–S212, 2006.
48. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest 67: 563–568, 1981.
49. DeFronzo RA, Beckles AD. Glucose intolerance following chronic metabolic acidosis in man. Am J Physiol Endocrinol Metab Gastrointest Physiol 236: E328–E334, 1979.
50. DeFronzo RA, Goldberg M, Agus ZS. The effects of glucose and insulin on renal electrolyte transport. J Clin Invest 58: 83–90, 1976.
51. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab Gastrointest Physiol 237: E214–E223, 1979.
52. DeFronzo RA, Tobin JD, Rowe JW, Andres R. Glucose intolerance in uremia: quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest 62: 425–435, 1978.
53. Dogra G, Irish A, Chan D, Watts G. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis 48: 926–934, 2006.
54. Dumler F, Kilates C. Body composition analysis by bioelectrical impedance in chronic maintenance dialysis patients: comparisons to the National Health and Nutrition Examination Survey III. J Ren Nutr 13: 166–172, 2003.
55. Dzurik R, Spustova V, Janekova K. The prevalence of insulin resistance in kidney disease patients before the development of renal failure. Nephron 69: 281–285, 1995.
56. Fadda GZ, Akmal M, Premdas FH, Lipson LG, Massry SG. Insulin release from pancreatic islets: effects of CRF and excess PTH. Kidney Int 33: 1066–1072, 1988.
57. Feldman HA, Singer I. Endocrinology and metabolism in uremia and dialysis: a clinical review. Medicine (Baltimore) 54: 345–376, 1975.
58. Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, Ritz E. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53: 1343–1347, 1998.
59. Folsom AR, Eckfeldt JH, Weitzman S, Ma J, Chambless LE, Barnes RW, Cram KB, Hutchinson RG. Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity: Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke 25: 66–73, 1994.
60. Friedman JE, Dohm GL, Elton CW, Rovira A, Chen JJ, Leggett-Frazier N, Atkinson SM Jr, Thomas FT, Long SD, Caro JF. Muscle insulin resistance in uremic humans: glucose transport, glucose transporters, and insulin receptors. Am J Physiol Endocrinol Metab 261: E87–E94, 1991.
61. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98: 2005–2010, 2001.
62. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426–430, 2005.
63. Giers K, Niemczyk S, Szamotulska K, Romejko-Ciepielewska K, Paklerska E, Bartoszewicz Z, Pacho R, Jasik M, Matuszkiewicz- Rowinska J. Visceral adipose tissue is associated with insulin resistance in hemodialyzed patients. Med Sci Monit 21: 557–562, 2015.
64. Goldberg AP, Hagberg JM, Delmez JA, Haynes ME, Harter HR. Metabolic effects of exercise training in hemodialysis patients. Kidney Int 18: 754–761, 1980.
65. Goodarzi MO, Cui J, Chen YD, Hsueh WA, Guo X, Rotter JI. Fasting insulin reflects heterogeneous physiological processes: role of insulin clearance. Am J Physiol Endocrinol Metab 301: E402–E408, 2011.
66. Graf H, Prager R, Kovarik J, Luger A, Schernthaner G, Pinggera WF. Glucose metabolism and insulin sensitivity in patients on chronic hemodialysis. Metabolism 34: 974–977, 1985.
67. Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven G. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes 30: 387–392, 1981.
68. Gu DF, Shi YL, Chen YM, Liu HM, Ding YN, Liu XY, Li YQ, Shao XF, Liang Y, Chen YS, Yuan ZY, Zou HQ. Prevalence of chronic kidney disease and prediabetes and associated risk factors: a communitybased screening in Zhuhai, Southern China. Chin Med J (Engl) 126: 1213–1219, 2013.
69. Guarnieri G, Zanetti M, Vinci P, Cattin MR, Barazzoni R. Insulin resistance in chronic uremia. J Ren Nutr 19: 20–24, 2009.
70. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91: 1578–1581, 2006.
71. Hanley AJ, Bowden D, Wagenknecht LE, Balasubramanyam A, Langfeld C, Saad MF, Rotter JI, Guo X, Chen YD, Bryer-Ash M, Norris JM, Haffner SM. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African- Americans. J Clin Endocrinol Metab 92: 2665–2671, 2007.
72. Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, Smith SR. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 89: 1844–1848, 2004.
73. Heimburger O, Lonnqvist F, Danielsson A, Nordenstrom J, Stenvinkel P. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 8: 1423–1430, 1997.
74. Henquin JC, Lambert AE. Bicarbonate modulation of glucose-induced biphasic insulin release by rat islets. Am J Physiol 231: 713–721, 1976.
75. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524–1538, 2002.
76. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, Okazaki Y, Ishii T, Oguma Y, Takei I, Saruta T. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51: 314–317, 2002.
77. Hivert MF, Sullivan LM, Fox CS, Nathan DM, D’Agostino RB, Sr, Wilson PW, Meigs JB. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 93: 3165–3172, 2008.
78. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, Frantz GD, Tumas DB, Peale FV Jr, Shelton DL, Hebert CC. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 19: 4046–4055, 2000.
79. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271: 665–668, 1996.
80. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595–1599, 2000.
81. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50: 1126–1133, 2001.
82. Howard G, O’Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R. Insulin sensitivity and atherosclerosis: the Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 93: 1809–1817, 1996.
83. Hughes R, Magee EA, Bingham S. Protein degradation in the large intestine: relevance to colorectal cancer. Curr Issues Intest Microbiol 1: 51–58, 2000.
84. Hung AM, Sundell MB, Egbert P, Siew ED, Shintani A, Ellis CD, Bian A, Ikizler TA. A comparison of novel and commonly-used indices of insulin sensitivity in African American chronic hemodialysis patients. Clin J Am Soc Nephrol 6: 767–774, 2011.
85. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I. Induction of adiponectin, a fat-derived antidi- abetic and antiatherogenic factor, by nuclear receptors. Diabetes 52: 1655–1663, 2003.
86. Jia T, Huang X, Qureshi AR, Xu H, Arnlov J, Lindholm B, Cederholm T, Stenvinkel P, Riserus U, Carrero JJ. Validation of insulin sensitivity surrogate indices and prediction of clinical outcomes in individuals with and without impaired renal function. Kidney Int 86: 383–391, 2014.
87. Jing C, Xu S, Ming J, Cai J, Zhang R, Shen H, Yang W, Ji Q. Insulin resistance is not independently associated with chronic kidney disease in Chinese population: a population-based cross-sectional study. Clin Chim Acta 448: 232–237, 2015.
88. Johansen KL, Chertow GM, Ng AV, Mulligan K, Carey S, Schoenfeld PY, Kent-Braun JA. Physical activity levels in patients on hemodialysis and healthy sedentary controls. Kidney Int 57: 2564–2570, 2000.
89. Kaartinen K, Syrjanen J, Porsti I, Harmoinen A, Pasternack A, Huhtala H, Niemela O, Mustonen J. Insulin resistance and the progression of IgA glomerulonephritis. Nephrol Dial Transplant 22: 778–783, 2007.
90. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28: 2289–2304, 2005.
91. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63: 793–808, 2003.
92. Kalbacher E, Koppe L, Zarrouki B, Pillon NJ, Fouque D, Soulage CO. Human uremic plasma and not urea induces exuberant secretion of leptin in 3T3-L1 adipocytes. J Ren Nutr 21: 72–75, 2011.
93. Kanauchi M, Kimura K, Akai Y, Saito Y. Insulin resistance and pancreatic beta-cell function in patients with hypertensive kidney disease. Nephrol Dial Transplant 19: 2025–2029, 2004.
94. Kanety H, Feinstein R, Papa MZ, Hemi R, Karasik A. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1): possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem 270: 23780–23784, 1995.
95. Karakan S, Sezer S, Ozdemir Acar FN. Insulin resistance and left ventricular mass in non-diabetic hemodialysis patients. Curr Ther Res Clin Exp 73: 165–173, 2012.
96. Karakan S, Sezer S, Ozdemir Acar FN, Haberal M. The relationship of visfatin levels with insulin resistance and left ventricular hypertrophy in peritoneal dialysis patients. Ren Fail 34: 732–737, 2012.
97. Kato Y, Hayashi M, Ohno Y, Suzawa T, Sasaki T, Saruta T. Mild renal dysfunction is associated with insulin resistance in chronic glomerulonephritis. Clin Nephrol 54: 366–373, 2000.
98. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85: 2402–2410, 2000.
99. Khedr E, El-Sharkawy M, Abdulwahab S, Eldin EN, Ali M, Youssif A, Ahmed B. Effect of recombinant human erythropoietin on insulin resistance in hemodialysis patients. Hemodial Int 13: 340–346, 2009.
100. Kielstein JT, Becker B, Graf S, Brabant G, Haller H, Fliser D. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 42: 62–66, 2003.
101. Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 298: F662–F671, 2010.
102. Kirchner KA. Insulin increases loop segment chloride reabsorption in the euglycemic rat. Am J Physiol Renal Fluid Electrolyte Physiol 255: F1206–F1213, 1988.
103. Klein LJ, Visser FC. The effect of insulin on the heart: part 1. Effects on metabolism and function. Neth Heart J 18: 197–201, 2010.
104. Kobayashi H, Tokudome G, Hara Y, Sugano N, Endo S, Suetsugu Y, Kuriyama S, Hosoya T. Insulin resistance is a risk factor for the progression of chronic kidney disease. Clin Nephrol 71: 643–651, 2009.
105. Kobayashi S, Maejima S, Ikeda T, Nagase M. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 15: 65–70, 2000.
106. Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 45: 275–280, 2005.
107. Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkuhn T, Parhofer KG, Goke B, Broedl UC. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 19: 1070–1074, 2007.
108. Koppe L, Pillon NJ, Vella RE, Croze ML, Pelletier CC, Chambert S, Massy Z, Glorieux G, Vanholder R, Dugenet Y, Soula HA, Fouque D, Soulage CO. p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol 24: 88–99, 2013.
109. Kopple JD, Kalantar-Zadeh K, Mehrotra R. Risks of chronic metabolic acidosis in patients with chronic kidney disease. Kidney Int Suppl 95, S21–S27, 2005.
110. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T, Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277: 25863–25866, 2002.
111. Kubota N, Yano W, Kubota T, Yamauchi T, Itoh S, Kumagai H, Kozono H, Takamoto I, Okamoto S, Shiuchi T, Suzuki R, Satoh H, Tsuchida A, Moroi M, Sugi K, Noda T, Ebinuma H, Ueta Y, Kondo T, Araki E, Ezaki O, Nagai R, Tobe K, Terauchi Y, Ueki K, Minokoshi Y, Kadowaki T. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 6: 55–68, 2007.
112. Kursat S, Colak HB, Toraman A, Tekce H, Ulman C, Bayturan O. Relationship of insulin resistance in chronic haemodialysis patients with inflammatory indicators, malnutrition, echocardiographic parameters and 24 hour ambulatory blood pressure monitoring. Scand J Urol Nephrol 44: 257–264, 2010.
113. Landau M, Kurella-Tamura M, Shlipak MG, Kanaya A, Strotmeyer E, Koster A, Satterfield S, Simsonick EM, Goodpaster B, Newman AB, Fried LF; Health, Aging and Body Composition Study. Body composition correlates of insulin resistance in older individuals with and without kidney disease. Nephrol Dial Transplant 26: 2814–2819, 2011.
114. Lee DM, Knight-Gibson C, Samuelsson O, Attman PO, Wang CS, Alaupovic P. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 61: 209–218, 2002.
115. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88: 4848–4856, 2003.
116. Leikis MJ, McKenna MJ, Petersen AC, Kent AB, Murphy KT, Leppik JA, Gong X, McMahon LP. Exercise performance falls over time in patients with chronic kidney disease despite maintenance of hemoglobin concentration. Clin J Am Soc Nephrol 1: 488–495, 2006.
117. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71: 31–38, 2007.
118. Li Y, Zhang L, Gu Y, Hao C, Zhu T. Insulin resistance as a predictor of cardiovascular disease in patients on peritoneal dialysis. Perit Dial Int 33: 411–418, 2013.
119. Liao MT, Sung CC, Hung KC, Wu CC, Lo L, Lu KC. Insulin resistance in patients with chronic kidney disease. J Biomed Biotechnol 2012: 691369, 2012.
120. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18: 1272–1280, 2003.
121. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension 38: 434–438, 2001.
122. Lumiaho A, Pihlajamaki J, Hartikainen J, Ikaheimo R, Miettinen R, Niemitukia L, Lampainen E, Laakso M. Insulin resistance is related to left ventricular hypertrophy in patients with polycystic kidney disease type 1. Am J Kidney Dis 41: 1219–1224, 2003.
123. Lupia E, Elliot SJ, Lenz O, Zheng F, Hattori M, Striker GE, Striker LJ. IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy. Diabetes 48: 1638–1644, 1999.
124. Madej T, Boguski MS, Bryant SH. Threading analysis suggests that the obese gene product may be a helical cytokine. FEBS Lett 373: 13–18, 1995.
125. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 221: 286–289, 1996.
126. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8: 731–737, 2002.
127. Maestro B, Campion J, Davila N, Calle C. Stimulation by 1,25- dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J 47: 383–391, 2000.
128. Magnusson M, Magnusson KE, Sundqvist T, Denneberg T. Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 32: 754–759, 1991.
129. Mak RH. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 53: 1353–1357, 1998.
130. Mak RH. Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia. Am J Physiol Renal Fluid Electrolyte Physiol 270: F839–F844, 1996.
131. Mak RH. Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 41: 1049–1054, 1992.
132. Mak RH. Metabolic effects of erythropoietin in patients on peritoneal dialysis. Pediatr Nephrol 12: 660–665, 1998.
133. Marshall S, Podlecki DA, Olefsky JM. Low pH accelerates dissociation of receptor-bound insulin. Endocrinology 113: 37–42, 1983.
134. Martins C, Mazza do Nascimento M, Pecoits-Filho R, Leinig C, Goncalves LF, Fuerbringer R, Stenvinkel P, Lindholm B, Riella MC. Insulin resistance is associated with circulating fibrinogen levels in nondiabetic patients receiving peritoneal dialysis. J Ren Nutr 17: 132–137, 2007.
135. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462–1470, 1999.
136. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419, 1985.
137. McCaleb ML, Mevorach R, Freeman RB, Izzo MS, Lockwood DH. Induction of insulin resistance in normal adipose tissue by uremic human serum. Kidney Int 25: 416–421, 1984.
138. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB. Leptin stimulates fatty-acid oxidation by activating AMPactivated protein kinase. Nature 415: 339–343, 2002.
139. Mohteshamzadeh M, Wong C, Whiticar R, Thomas S. Is there a link between insulin resistance and chronic kidney disease in men with treated hypertension? Analysis of 5-year data. Am J Nephrol 29: 116–122, 2009.
140. Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ, Draznin B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 277: 1794–1799, 2002.
141. Mooney A, Jobson T, Bacon R, Kitamura M, Savill J. Cytokines promote glomerular mesangial cell survival in vitro by stimulus-dependent inhibition of apoptosis. J Immunol 159: 3949–3960, 1997.
142. Moreno-Navarrete JM, Catalan V, Ortega F, Gomez-Ambrosi J, Ricart W, Fruhbeck G, Fernandez-Real JM. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 7: 27, 2010.
143. Morrisey K, Evans RA, Wakefield L, Phillips AO. Translational regulation of renal proximal tubular epithelial cell transforming growth factor-beta1 generation by insulin. Am J Pathol 159: 1905–1915, 2001.
144. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 28: 463–491, 2007.
145. Nagaev I, Bokarewa M, Tarkowski A, Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS One 1: e31, 2006.
146. Nand N, Jain P, Sharma M. Insulin resistance in patients of end-stage renal disease (ESRD) on haemodialysis: effect of short-term erythropoietin therapy. J Ind Acad Clin Med 15: 13–16, 2014.
147. Naughton J, Leonard F. A conceptual model for rehabilitation. Med Ann Dist Columbia 42: 6–8, 1973.
148. Nerpin E, Riserus U, Ingelsson E, Sundstrom J, Jobs M, Larsson A, Basu S, Arnlov J. Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a communitybased cohort. Diabetes Care 31: 1550–1555, 2008.
149. Ng KW, Allen ML, Desai A, Macrae D, Pathan N. Cardioprotective effects of insulin: how intensive insulin therapy may benefit cardiac surgery patients. Circulation 125: 721–728, 2012.
150. Nickenig G, Roling J, Strehlow K, Schnabel P, Bohm M. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 98: 2453–2460, 1998.
151. Osawa H, Tabara Y, Kawamoto R, Ohashi J, Ochi M, Onuma H, Nishida W, Yamada K, Nakura J, Kohara K, Miki T, Makino H. Plasma resistin, associated with single nucleotide polymorphism 420, is correlated with insulin resistance, lower HDL cholesterol, and highsensitivity C-reactive protein in the Japanese general population. Diabetes Care 30: 1501–1506, 2007.
152. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102: 1296–1301, 2000.
153. Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 88: 29–33, 2010.
154. Park JH, Oh SW, Ahn SY, Kim S, Na KY, Chae DW, Kim S, Chin HJ. Decreased estimated glomerular filtration rate is not directly related to increased insulin resistance. Diabetes Res Clin Pract 99: 366–371, 2013.
155. Pelletier CC, Koppe L, Croze ML, Kalbacher E, Vella RE, Guebre- Egziabher F, Geloen A, Badet L, Fouque D, Soulage CO. White adipose tissue overproduces the lipid-mobilizing factor zinc alpha2- glycoprotein in chronic kidney disease. Kidney Int 83: 878–886, 2013.
156. Perticone F, Maio R, Ruberto C, Cassano S, Tripepi G, Perticone M, Sesti G, Zoccali C. Kidney function and risk factors for left ventricular hypertrophy in untreated uncomplicated essential hypertension. Am J Kidney Dis 52: 74–84, 2008.
157. Petchey WG, Hickman IJ, Prins JB, Hawley CM, Johnson DW, Isbel NM, Duncan EL. Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3–4: a randomized controlled trial. Nephrology (Carlton) 18: 26–35, 2013.
158. Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell JM. Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation 93: 1331–1333, 1996.
159. Pham H, Robinson-Cohen C, Biggs ML, Ix JH, Mukamal KJ, Fried LF, Kestenbaum B, Siscovick DS, de Boer IH. Chronic kidney disease, insulin resistance, and incident diabetes in older adults. Clin J Am Soc Nephrol 7: 588–594, 2012.
160. Piatti PM, Monti LD, Conti M, Baruffaldi L, Galli L, Phan CV, Guazzini B, Pontiroli AE, Pozza G. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 45: 316–321, 1996.
161. Pizzarelli F, Dattolo P, Ferdeghini EM, Morales MA. Parameters derived by ultrasonic myocardial characterization in dialysis patients are associated with mortality. Kidney Int 68: 1320–1325, 2005.
162. Plomgaard P, Fischer CP, Ibfelt T, Pedersen BK, van Hall G. Tumor necrosis factor-alpha modulates human in vivo lipolysis. J Clin Endocrinol Metab 93: 543–549, 2008.
163. Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia 27: 351–357, 1984.
164. Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, Sinha MK, Gingerich RL, Scherer PE, Ahima RS. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 53: 1671–1679, 2004.
165. Rea R, Donnelly R. Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity? Diabetes Obes Metab 6: 163–170, 2004.
166. Reaich D, Graham KA, Channon SM, Hetherington C, Scrimgeour CM, Wilkinson R, Goodship TH. Insulin-mediated changes in PD and glucose uptake after correction of acidosis in humans with CRF. Am J Physiol Endocrinol Metab 268: E121–E126, 1995.
167. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 37: 1595–1607, 1988.
168. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111: 932–939, 2005.
169. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6: 363–375, 2007.
170. Rieusset J, Bouzakri K, Chevillotte E, Ricard N, Jacquet D, Bastard JP, Laville M, Vidal H. Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 53: 2232–2241, 2004.
171. Rocchini AP, Katch V, Kveselis D, Moorehead C, Martin M, Lampman R, Gregory M. Insulin and renal sodium retention in obese adolescents. Hypertension 14: 367–374, 1989.
172. Rudich A, Tirosh A, Potashnik R, Hemi R, Kanety H, Bashan N. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 47: 1562–1569, 1998.
173. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277: 42394–42398, 2002.
174. Ruiz S, Pergola PE, Zager RA, Vaziri ND. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 83: 1029–1041, 2013.
175. Sanchez-Villanueva R, Estrada P, del Peso G, Grande C, Diez JJ, Iglesias P, Gonzalez E, Aguilar-Rodriguez A, Selgas R, Bajo MA; Grupo de Estudios Peritoneales de Madrid de REDINREN (Red Renal de Investigación de la RETICS 06/0016, del Instituto de Salud Carlos III); del IRSIN (Instituto Reina Sofía de Investigación Nefrológica). Repeated analysis of estimated insulin resistance using the HOMAIR index in nondiabetic patients on peritoneal dialysis and its relationship with cardiovascular disease and mortality [in Spanish]. Nefrologia 33: 85–92, 2013.
176. Sarathy H, Pramanik V, Kahn J, Abramowitz MK, Meier K, Kishore P, Melamed ML. The effects of short-term vitamin D supplementation on glucose metabolism in dialysis patients: a systematic review and meta-analysis. Int Urol Nephrol 47: 537–549, 2015.
177. Sarzani R, Dessi-Fulgheri P, Salvi F, Serenelli M, Spagnolo D, Cola G, Pupita M, Giantomassi L, Rappelli A. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens 17: 1301–1305, 1999.
178. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci U S A 88: 9959–9963, 1991.
179. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest 116: 1813–1822, 2006.
180. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51: 3391–3399, 2002.
181. Sergeev IN, Rhoten WB. 1,25-Dihydroxyvitamin D3 evokes oscillations of intracellular calcium in a pancreatic beta-cell line. Endocrinology 136: 2852–2861, 1995.
182. Shechter Y, Ron A. Effect of depletion of bicarbonate or phosphate ions on insulin action in rat adipocytes: further characterization of the receptor- effector system. J Biol Chem 261: 14951–14954, 1986.
183. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 13: 1894–1900, 2002.
184. Shinohara K, Shoji T, Tsujimoto Y, Kimoto E, Tahara H, Koyama H, Emoto M, Ishimura E, Miki T, Tabata T, Nishizawa Y. Arterial stiffness in predialysis patients with uremia. Kidney Int 65: 936–943, 2004.
185. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 334: 1092–1101, 2005.
186. Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME. The prevalence of insulin resistance in nondiabetic nonobese patients with chronic kidney disease. Adv Ther 23: 988–998, 2006.
187. Sit D, Kadiroglu AK, Yilmaz ME, Kara IH, Isikoglu B. The prevalence of insulin resistance and its relationship between anemia, secondary hyperparathyroidism, inflammation, and cardiac parameters in chronic hemodialysis patients. Ren Fail 27: 403–407, 2005.
188. Skott P, Hother-Nielsen O, Bruun NE, Giese J, Nielsen MD, Beck- Nielsen H, Parving HH. Effects of insulin on kidney function and sodium excretion in healthy subjects. Diabetologia 32: 694–699, 1989.
189. Smith JS, Pace CS. Modification of glucose-induced insulin release by alteration of pH. Diabetes 32: 61–66, 1983.
190. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37: 1053–1059, 2001.
191. Spaia S, Pangalos M, Askepidis N, Pazarloglou M, Mavropoulou E, Theodoridis S, Dimitrakopoulos K, Milionis A, Vayonas G. Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients. Nephron 84: 320–325, 2000.
192. Spoto B, Testa A, Parlongo RM, Tripepi G, D’Arrigo G, Mallamaci F, Zoccali C. Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure. Nephrol Dial Transplant 27: 2440–2445, 2012.
193. Spoto B, Testa A, Parlongo RM, Tripepi G, Trischitta V, Mallamaci F, Zoccali C. Insulin resistance and left ventricular hypertrophy in end-stage renal disease: association between the ENPP1 gene and left ventricular concentric remodelling. Nephrol Dial Transplant 27: 661–666, 2012.
194. Stefanovic V, Djordjevic V, Ivic M, Mitic-Zlatkovic M, Vlahovic P. Lymphocyte PC-1 activity in patients on maintenance haemodialysis treated with human erythropoietin and 1-alpha-D3. Ann Clin Biochem 42: 55–60, 2005.
195. Stefikova K, Spustova V, Krivosikova Z, Dzurik R. Insulin resistance in kidney disease patients with mild to moderate kidney disease. Bratisl Lek Listy 105: 397–399, 2004.
196. Stefikova K, Spustova V, Krivosikova Z, Oksa A, Gazdikova K, Fedelesova V, Dzurik R. Insulin resistance and vitamin D deficiency in patients with chronic kidney disease stage 2–3. Physiol Res 60: 149–155, 2011.
197. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 51: 527–539, 2008.
198. Stenvinkel P, Marchlewska A, Pecoits-Filho R, Heimburger O, Zhang Z, Hoff C, Holmes C, Axelsson J, Arvidsson S, Schalling M, Barany P, Lindholm B, Nordfors L. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 65: 274–281, 2004.
199. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 409: 307–312, 2001.
200. Stout RW, Bierman EL, Ross R. Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res 36: 319–327, 1975.
201. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, Renn W, Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23: 295–301, 2000.
202. Sunden-Cullberg J, Nystrom T, Lee ML, Mullins GE, Tokics L, Andersson J, Norrby-Teglund A, Treutiger CJ. Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit Care Med 35: 1536–1542, 2007.
203. Takenaka T, Kanno Y, Ohno Y, Suzuki H. Key role of insulin resistance in vascular injury among hemodialysis patients. Metabolism 56: 153–159, 2007.
204. Tatar E, Demirci MS, Kircelli F, Gungor O, Turan MN, Sevinc Ok E, Asci G, Ozkahya M, Ok E. Association of insulin resistance with arterial stiffness in nondiabetic peritoneal dialysis patients. Int Urol Nephrol 44: 255–262, 2012.
205. Trirogoff ML, Shintani A, Himmelfarb J, Ikizler TA. Body mass index and fat mass are the primary correlates of insulin resistance in nondiabetic stage 3–4 chronic kidney disease patients. Am J Clin Nutr 86: 1642–1648, 2007.
206. Tuzcu A, Bahceci M, Yilmaz E, Bahceci S, Tuzcu S. The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin. Horm Metab Res 36: 716–720, 2004.
207. Unger RH. Lipotoxic diseases. Annu Rev Med 53: 319–336, 2002.
208. Vareesangthip K, Tong P, Wilkinson R, Thomas TH. Insulin resistance in adult polycystic kidney disease. Kidney Int 52: 503–508, 1997.
209. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL. Chronic kidney disease alters intestinal microbial flora. Kidney Int 83: 308–315, 2013.
210. Walker BG, Phear DN, Martin FI, Baird CW. Inhibition of insulin by acidosis. Lancet 2: 964–965, 1963.
211. Wang CJ, Bao XR, Du GW, Wang Y, Chen K, Shen ML, Wang LZ. Effects of insulin resistance on left ventricular hypertrophy in patients with CKD stage 1–3. Int Urol Nephrol 46: 1609–1617, 2014.
212. Wang T, Zhang X, Bheda P, Revollo JR, Imai S, Wolberger C. Structure of Nampt/PBEF/visfatin, a mammalian NAD biosynthetic enzyme. Nat Struct Mol Biol 13: 661–662, 2006.
213. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86: 1930–1935, 2001.
214. Widmer B, Gerhardt RE, Harrington JT, Cohen JJ. Serum electrolyte and acid base composition: the influence of graded degrees of chronic renal failure. Arch Intern Med 139: 1099–1102, 1979.
215. Wright VP, Reiser PJ, Clanton TL. Redox modulation of global phosphatase activity and protein phosphorylation in intact skeletal muscle. J Physiol 587: 5767–5781, 2009.
216. Xu H, Huang X, Arnlov J, Cederholm T, Stenvinkel P, Lindholm B, Riserus U, Carrero JJ. Clinical correlates of insulin sensitivity and its association with mortality among men with CKD stages 3 and 4. Clin J Am Soc Nephrol 9: 690–697, 2014.
217. Xue P, Hou Y, Chen Y, Yang B, Fu J, Zheng H, Yarborough K, Woods CG, Liu D, Yamamoto M, Zhang Q, Andersen ME, Pi J. Adipose deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome. Diabetes 62: 845–854, 2013.
218. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T. Globular adiponectin protected ob/ob mice from diabetes and ApoEdeficient mice from atherosclerosis. J Biol Chem 278: 2461–2468, 2003.
219. Yang RZ, Huang Q, Xu A, McLenithan JC, Eisen JA, Shuldiner AR, Alkan S, Gong DW. Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun 310: 927–935, 2003.
220. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 290: E1253–E1261, 2006.
221. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, Sonmez A, Cakir E, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 23: 959–965, 2008.
222. Yoo DE, Lee MJ, Oh HJ, Kim SJ, Shin DH, Yoo TH, Kang SW, Choi KH, Han DS, Han SH. Low circulating adiponectin levels are associated with insulin resistance in non-obese peritoneal dialysis patients. Endocr J 59: 685–695, 2012.
223. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51: 2968–2974, 2002.
224. Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 6: 30–39, 2011.
225. Zhang Y, Lee ET, Howard BV, Best LG, Umans JG, Yeh J, Wang W, Yeh F, Ali T, Devereux RB, de Simone G. Insulin resistance, incident cardiovascular diseases, and decreased kidney function among nondiabetic American Indians: the Strong Heart Study. Diabetes Care 36: 3195–3200, 2013.
226. Zhao AZ, Bornfeldt KE, Beavo JA. Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Invest 102: 869–873, 1998.
227. Zhou Y, Yu Z, Jia H, Sun F, Ma L, Guo R, Peng L, Cui T. Association between insulin resistance and carotid arterial stiffness in nondiabetic hemodialysis patients. Blood Purif 28: 193–199, 2009.
228. Zoccali C, Bolignano D, Mallamaci F. Left ventricular hypertrophy in chronic kidney disease. In: Oxford Textbook of Clinical Nephrology. New York: Oxford University Press, 2016, p. 837–852.
229. Zoccali C, Mallamaci F, Tripepi G. Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease. Kidney Int Suppl 84: S65–S68, 2003.
230. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13: 134–141, 2002.
231. Zoccali C, Tripepi G, Cambareri F, Catalano F, Finocchiaro P, Cutrupi S, Pizzini P, Testa A, Spoto B, Panuccio V, Enia G, Mallamaci F. Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease patients. J Ren Nutr 15: 125–130, 2005.